Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Rating) is one of 277 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it compare to its rivals? We will compare Fresh Tracks Therapeutics to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.
Profitability
This table compares Fresh Tracks Therapeutics and its rivals' net margins, return on equity and return on assets.
Get Fresh Tracks Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Fresh Tracks Therapeutics | -453.11% | -133.55% | -108.52% |
| Fresh Tracks Therapeutics Competitors | -4,576.34% | -104.23% | -37.17% |
Risk and Volatility
Fresh Tracks Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics' rivals have a beta of 0.75, suggesting that their average share price is 25% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Fresh Tracks Therapeutics and its rivals, as reported by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresh Tracks Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Fresh Tracks Therapeutics Competitors | 895 | 3857 | 10720 | 160 | 2.65 |
Fresh Tracks Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 61.29%. As a group, "Biological products, except diagnostic" companies have a potential upside of 70.07%. Given Fresh Tracks Therapeutics' rivals higher probable upside, analysts plainly believe Fresh Tracks Therapeutics has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares Fresh Tracks Therapeutics and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresh Tracks Therapeutics | $400,000.00 | -$39.47 million | -0.30 |
| Fresh Tracks Therapeutics Competitors | $767.19 million | $146.84 million | -2.01 |
Fresh Tracks Therapeutics' rivals have higher revenue and earnings than Fresh Tracks Therapeutics. Fresh Tracks Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
7.7% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 46.5% of shares of all "Biological products, except diagnostic" companies are owned by institutional investors. 4.5% of Fresh Tracks Therapeutics shares are owned by company insiders. Comparatively, 16.3% of shares of all "Biological products, except diagnostic" companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Fresh Tracks Therapeutics rivals beat Fresh Tracks Therapeutics on 8 of the 10 factors compared.
About Fresh Tracks Therapeutics
(Get Rating)
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.